<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578382</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-NR2010-0433/0</org_study_id>
    <nct_id>NCT01578382</nct_id>
  </id_info>
  <brief_title>Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU)</brief_title>
  <official_title>Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU): A Comparison of Martorell HYTILU, Calciphylaxis and Venous Ulcer (Control)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Martorell hypertensive ischemic leg ulcer is a severe type of skin necrosis (skin infarction)&#xD;
      which occurs in long-term hypertensive subjects.&#xD;
&#xD;
      Calciphylaxis (calcific uremic arteriolopathy) is a severe type of skin necrosis (skin&#xD;
      infarction) which occurs in subjects with end-stage kidney disease or after kidney&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparative study including&#xD;
&#xD;
        -  20 consecutive patients with Martorell HYTILU&#xD;
&#xD;
        -  10 consecutive patients with Calciphylaxis (calcific uremic arteriolopathy)&#xD;
&#xD;
        -  20 patients with venous ulcer&#xD;
&#xD;
      The following parameters are measured in the blood serum:&#xD;
&#xD;
      White blood count; c-reactive protein; creatinine; calcium (total); free (ionized) calcium;&#xD;
      phosphate; albumin; 25-hydroxyvitamin-D; 1-25-dihydroxyvitamin-D; homocysteine; cystatin C&#xD;
      alphafetoin, osteoprotegerin; fibroblast growth factor 23 (FGF-23); globular arrest 1 (GLA-1)&#xD;
&#xD;
      The following parameters are measured in samples of diseased (necrobiotic) skin:&#xD;
&#xD;
      alphafetoin, osteoprotegerin; fibroblast growth factor 23 (FGF-23); globular arrest 1 (GLA-1)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Martorell HYTILU and calciphylaxis show both decreased tissue protection mechanisms against tissue calcification</measure>
    <time_frame>36 months</time_frame>
    <description>Comparison of the calcification-protective factors GLA-1(serum protein alpha2-Heremans-Schmid glycoprotein/fetuin A), Osteoprotegerin, Fibroblast Growth Factor 23, and Alphafetoin in:&#xD;
Martorell HYTILU (A1)&#xD;
Calciphylaxis (calcific uremic arteriolopathy)(A2)&#xD;
Venous ulcers (as control group)(B)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Martorell hypertensive ischemic leg ulcer and calciphylaxis are both characterized by non-infectious inflammation</measure>
    <time_frame>36 months</time_frame>
    <description>Comparison of C-reactive protein, procalcitonin and white blood cell count in:&#xD;
Martorell HYTILU (A1)&#xD;
Calciphylaxis (calcfic uremic arteriolopathy) (A2)&#xD;
Venous ulcers (control group) (B)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Hypertensive Ischemic Leg Ulcer</condition>
  <condition>Calciphylaxis</condition>
  <arm_group>
    <arm_group_label>Hypertensive ischemic leg ulcer</arm_group_label>
    <description>Twenty consecutive patients with Martorell HYTILU as defined in:&#xD;
Arch Dermatol 2010;146:961-968</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calciphylaxis</arm_group_label>
    <description>Ten subjects with calciphylaxis (calcific uremic arteriolopathy) as described in:&#xD;
Vasa 1998;27:137-143</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venous ulcer (controls)</arm_group_label>
    <description>Twenty subjects with venous ulcers (CEAP C4-6) as described in:&#xD;
J Vasc Surg. 2004 Dec;40(6):1248-52</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum (2 tubes); blood plasma in citrate (2 tubes); blood plasma in heparin (2 tubes)&#xD;
      Diseased skin tissue in formalin for paraffin embedded H-E histology; Diseased skin tissue&#xD;
      snap frozen Diseased skin tissue in &quot;RNA later&quot; tube (1 tube)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        n=20: Having Martorell hypertensive ischemic leg ulcer (as defined above) or n=10: Having&#xD;
        Calciphylaxis (calcific uremic arteriolopathy (as defined above) or n=20: Having a venous&#xD;
        ulcer (as defined above) (controls)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having Martorell hypertensive ischemic leg ulcer (as defined above) or&#xD;
&#xD;
          -  Having Calciphylaxis (calcific uremic arteriolopathy (as defined above) or&#xD;
&#xD;
          -  Having a venous ulcer (as defined above)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JÃ¼rg Hafner, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, University Hospital of Zurich, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, University Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Martorell hypertensive ischemic leg ulcer</keyword>
  <keyword>Calciphylaxis (calcific uremic arteriolopathy)</keyword>
  <keyword>Ischemic subcutaneous arteriolosclerosis</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Medial calcinosis</keyword>
  <keyword>Wound healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Calciphylaxis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

